Core Insights - Maiwei Biotech has received approval from the National Medical Products Administration (NMPA) for its IL-11 monoclonal antibody 9MW3811 to enter Phase II clinical trials for pathological scars, marking it as the first drug targeting this indication in clinical exploration [1] - The company has established an exclusive licensing agreement with CALICO Life Sciences, which includes an upfront payment of $25 million and potential milestone payments totaling up to $571 million, along with tiered royalties based on net sales [1][2] - Maiwei Biotech reported a significant revenue increase of 301.03% year-on-year, reaching 566 million yuan in the first three quarters of 2025, driven primarily by income from innovative product collaborations [2] Group 1: Clinical Development and Partnerships - The company has a comprehensive pipeline with 15 core products at various stages, including 11 innovative drugs and 4 biosimilars, focusing on oncology and age-related diseases [2] - The Phase II clinical trial for the anti-TMPRSS6 monoclonal antibody 9MW3011 has commenced, with the first patient dosed in the U.S., marking a significant milestone in its collaboration with DISC Medicine [3] - Maiwei Biotech has entered into a partnership with Qilu Pharmaceutical for long-acting white blood cell-boosting drugs, with a contract value of up to 500 million yuan, including a non-refundable upfront payment of 380 million yuan [4] Group 2: Financial Performance - The substantial increase in technical service revenue is attributed to the licensing agreements with CALICO, Qilu, and DISC, indicating the successful commercialization of innovative research [4] - The company’s revenue from technical services reached 407 million yuan, a year-on-year increase of 715.52%, while drug sales contributed 156 million yuan, reflecting a 72.10% increase [2] - Maiwei Biotech's ongoing clinical trials for its core pipeline products, including 9MW2821 and JS207, show promising efficacy signals in treating triple-negative breast cancer [5]

11月13日，有消息称国内一家生物制药企业解散肿瘤销售团队，信息指向迈威生物。对此，智通财经记 者致电迈威生物董秘办/证代公开电话，接电人员表示公司未解散肿瘤销售团队，但也未告知记者目前 肿瘤销售团队人员数量，仅表示公司有统计研发人员数量，并在财报中披露。此后，记者再次联系迈威 生物，公司表示不回应此事。（智通财经） ...

数据显示，易方达基金旗下1只基金位居迈威生物十大流通股东。易方达医疗保健行业混合A （110023）三季度新进十大流通股东，持有股数317.46万股，占流通股的比例为1.55%。根据测算，今 日浮盈赚取约704.76万元。 易方达医疗保健行业混合A（110023）成立日期2011年1月28日，最新规模38.02亿。今年以来收益 35.72%，同类排名2184/8145；近一年收益22.42%，同类排名3130/8059；成立以来收益313.4%。 易方达医疗保健行业混合A（110023）基金经理为杨桢霄。 11月13日，迈威生物涨5.07%，截至发稿，报45.98元/股，成交1.28亿元，换手率1.40%，总市值183.74 亿元。 截至发稿，杨桢霄累计任职时间9年88天，现任基金资产总规模98.16亿元，任职期间最佳基金回报 209.21%， 任职期间最差基金回报-15.64%。 资料显示，迈威(上海)生物科技股份有限公司位于中国(上海)自由贸易试验区蔡伦路230号2幢105室香港 铜锣湾希慎道33号利园1期19楼1928室，成立日期2017年5月12日，上市日期2022年1月18日，公司主营 业务涉及治疗 ...

Group 1 - The core point of the article highlights the recent performance of Maiwei Biotech, which saw a 5.02% increase in stock price, reaching 44.59 CNY per share, with a trading volume of 214 million CNY and a turnover rate of 2.41%, resulting in a total market capitalization of 17.818 billion CNY [1] - Maiwei Biotech, established on May 12, 2017, and listed on January 18, 2022, is primarily engaged in the research, production, and sales of therapeutic biological products, with 99.91% of its revenue coming from product sales and 0.09% from services [1] Group 2 - From the perspective of fund holdings, a fund under AVIC Fund has a significant position in Maiwei Biotech, with the AVIC Optimal Navigation Mixed Fund A (022852) holding 891,100 shares, accounting for 9.89% of the fund's net value, making it the seventh-largest holding [2] - The AVIC Optimal Navigation Mixed Fund A (022852) has achieved a return of 73.81% year-to-date, ranking 222 out of 8147 in its category, and has a total fund size of 606.1 million CNY [2] Group 3 - The fund manager of AVIC Optimal Navigation Mixed Fund A is Wang Sen, who has been in the position for 2 years and 48 days, overseeing a total asset size of 2.85 billion CNY, with the best fund return during his tenure being 136.74% and the worst being 2.83% [3]

Core Insights - The report highlights the performance of the domestic financial market, with the Shanghai Composite Index closing at 4002.76, down 0.39% [4] - The retail sales of new energy passenger vehicles reached 1.282 million units in October, marking a year-on-year increase of 7.3% and a cumulative retail of 10.151 million units from January to October, reflecting a growth of 21.9% [6] - The report discusses the increasing market scale in the express delivery industry, indicating a seasonal growth trend [8] Industry Updates - Multiple departments have jointly issued documents to promote the open interconnection of enterprise logistics data, with related stocks including SuperMap Software (300036) and Hezhong Shizhuang (002383) [8] - Two departments have issued documents to strengthen the technological innovation support for new energy consumption, with related stocks including Southern Power Grid Technology (688248) and Oriental Electronics (000682) [8] - The express delivery industry is showing signs of seasonal characteristics, with accelerated market growth and related stocks including YTO Express (600233) and Shentong Express (002468) [8] Company Focus - Maiwei Biotech (688062) has received approval from the National Medical Products Administration for a Phase II clinical trial application for its MW3811 injection for pathological scars, with trials expected to start by the end of 2025 [10] - Zhongbei Communication (603220) has signed a comprehensive service framework agreement with Xiamen Hongxin Electronic Technology Group to collaborate on computing resource services [10] - Chaoying Electronics (603175) plans to expand its AI computing high-end printed circuit board production project in Thailand [10] Market Review and Outlook - On November 11, the total trading volume in the two markets was 1.9936 trillion yuan, with 2631 stocks rising and 2380 stocks falling, indicating a net outflow of 76.83 billion yuan [12] - The report notes that the market is experiencing a weak recovery with a focus on speculative trading, while trends in battery and photovoltaic sectors show relative resilience [13] - The report suggests that if the market experiences a pullback, investors may consider low-risk opportunities in resilient sectors for trial trading [13]

Core Insights - On November 11, Maiwei Biotech experienced a decline of 1.28% with a trading volume of 296 million yuan, indicating market volatility [1] - The company reported a financing buy-in of 41.07 million yuan and a net financing buy of 11.31 million yuan on the same day, reflecting investor interest despite the stock price drop [1] - As of November 11, the total margin balance for Maiwei Biotech reached 612 million yuan, which is 7.05% of its market capitalization, suggesting a high level of leverage [1] Financing Summary - On November 11, the financing buy-in was 41.07 million yuan, with a total financing balance of 611 million yuan, exceeding the 80th percentile of the past year [1] - The margin trading showed a repayment of 200 shares and a sell-off of 1,100 shares, with a total sell amount of 46,700 yuan, indicating active trading [1] - The current margin balance of 955,300 yuan also exceeds the 80th percentile of the past year, indicating a high level of short selling activity [1] Company Performance - As of September 30, the number of shareholders for Maiwei Biotech increased by 9.15% to 19,600, while the average number of circulating shares per person decreased by 8.38% to 10,425 shares [2] - For the period from January to September 2025, the company achieved a revenue of 566 million yuan, representing a year-on-year growth of 301.03%, while the net profit attributable to shareholders was -598 million yuan, showing a 13.89% increase [2] - Among the top ten circulating shareholders, new entrants include E Fund Healthcare Industry Mixed A and Southern CSI 1000 ETF, while some previous shareholders have exited the list [2]

Group 1: Regulatory Developments - The National Healthcare Security Administration (NHSA) held a public seminar on the adjustment of the Disease-Based Payment Grouping Scheme 3.0, engaging with representatives from 22 hospitals [1] - The National Medical Products Administration (NMPA) issued technical guidelines for the pharmaceutical research and evaluation of recombinant glycoprotein hormone products [2] Group 2: Clinical Trials and Approvals - Maiwei Biotech announced that its 9MW3811 injection for pathological scars has received approval for a Phase II clinical trial, with plans to start by the end of 2025 [3] - Yuandong Biotech reported that its YLSH003 injection for advanced solid tumors has initiated Phase I/II clinical trials, with the first subject successfully enrolled [4] - Novartis received FDA approval for Remibrutinib tablets for treating chronic spontaneous urticaria (CSU) in adults who remain symptomatic after H1 antihistamine treatment [5] Group 3: Market Activities - Real Bio Technology has submitted a listing application to the Hong Kong Stock Exchange, marking its third attempt to go public [6] - Kangfang Biotech announced the completion of the first patient dosing in a Phase I trial for its personalized mRNA vaccine AK154, used in combination with other therapies for postoperative pancreatic cancer treatment [6] Group 4: Research Breakthroughs - Researchers from Monash University and the University of Warwick discovered a promising antibiotic during the production process of a common drug, effective against "superbugs" like methicillin-resistant Staphylococcus aureus [7]

Core Viewpoint - Maiwei Biotech has received approval from the National Medical Products Administration for the clinical trial application of 9MW3811 injection for the treatment of pathological scars, marking a significant step in its drug development process [2][4]. Drug Basic Information - Drug Name: 9MW3811 Injection - Application: Clinical trial for domestic drug registration - Applicant: Maiwei Biotech - Clinical Trial Notification Number: 2025LP02967 - Approval Conclusion: The application meets the requirements for drug registration and is approved to proceed with clinical trials [2]. Drug Mechanism and Potential - IL-11 is a cytokine involved in chronic inflammation and fibrosis-related diseases, playing a crucial role in the fibrotic processes of various organs [3]. - Pathological scars include hypertrophic scars, keloids, and contracture scars, with IL-11 being particularly significant in their formation [3]. - 9MW3811 is a humanized monoclonal antibody targeting IL-11, designed to inhibit the abnormal activation of the IL-11/IL-11Rα signaling pathway, thus intervening in the pathological progression of fibrosis-related diseases [4]. Clinical Development and Market Potential - 9MW3811 has shown significant efficacy in preclinical studies for pulmonary fibrosis and other fibrosis-related diseases, with a global patient population of approximately 25 million for pathological scars, including about 7.4 million in China [4]. - The company plans to initiate Phase II clinical trials for 9MW3811 targeting pathological scars by the end of 2025, positioning it as the first IL-11 targeted drug to enter clinical stages for this indication [5]. - Maiwei Biotech has entered into an exclusive licensing agreement with CALICO LIFE SCIENCES LLC, which includes an upfront payment of $25 million and potential milestone payments totaling up to $571 million, indicating strong commercial prospects for 9MW3811 [5].

Group 1 - Digital Zhengtong's subsidiary Baoding Jindi won a bid for a smart water project in Jinan, with a total contract value of 109 million yuan, of which Baoding Jindi's share is approximately 77 million yuan [1] - Lingzhi Software plans to acquire 100% equity of Kaimiride through a combination of cash and stock issuance, with the final transaction price yet to be determined [1] - Tianjin Port's subsidiary plans to transfer 60% equity of China Railway Storage and Transportation, with an estimated value of 37.54 million yuan for the entire equity [2] Group 2 - New Wufeng reported a 56.97% year-on-year increase in pig sales in October, selling 610,000 pigs [3] - New Peng Co. announced a joint investment of approximately 15 million USD with Jabil to build a battery storage box project in Thailand [4] - Maiwei Bio received approval for a clinical trial of its 9MW3811 injection for pathological scars [6] Group 3 - Jiangsu Sopo completed maintenance and resumed production of its methanol and acetic acid facilities [8] - Luoniushan reported a 24.65% year-on-year increase in pig sales revenue in October, totaling 116 million yuan [9][10] - Zhongbei Communication signed a 1 billion yuan comprehensive computing service framework agreement with Xiamen Hongxin Electronics [11] Group 4 - Huayang New Materials announced the resignation of its general manager, Wu Yuehua [12] - Zhongxin Co. used 50 million yuan of idle funds to purchase structured deposits with expected annual returns between 0.55% and 2.05% [14] - Huajian Group's subsidiary signed a construction engineering design contract worth 96.54 million yuan [16] Group 5 - Jianyou Co. received FDA approval for a new production site for its injectable drug [17] - Beilu Pharmaceutical obtained a drug registration certificate for its iodine mepivacaine injection, which is included in the national medical insurance catalog [19] - *ST Yuancheng's stock will be suspended due to falling below the market cap threshold for delisting [20] Group 6 - Xiantan Co. reported a 9.3% year-on-year increase in chicken product sales revenue in October, totaling 503 million yuan [21] - Huanxu Electronics reported an 8.93% year-on-year decrease in consolidated revenue for October, amounting to 5.598 billion yuan [23] - Yisheng Co. reported a 22.97% year-on-year decrease in white feather chicken seed sales revenue in October [25] Group 7 - Yuandong Bio initiated a Phase I/II clinical trial for its ADC drug YLSH003 targeting advanced solid tumors [25] - Xiaoming Co. reported a 34.89% year-on-year decrease in chicken product sales revenue in October [26] - Nanjiao Food reported a 5.27% year-on-year decrease in consolidated revenue for October, totaling 235 million yuan [28] Group 8 - Chuangye Huikang announced a potential change in control, leading to a temporary stock suspension [30] - Tangrenshen reported a 17.91% year-on-year decrease in pig sales revenue in October, totaling 828 million yuan [32][33] - Wancheng Group plans to distribute a cash dividend of 1.5 yuan per 10 shares to shareholders [34] Group 9 - Kangguan Technology plans to distribute a cash dividend of 3.6 yuan per 10 shares to shareholders [36] - Shoudu Online's executive plans to reduce holdings of up to 19,400 shares [38] - Maolai Optical received approval for the issuance of convertible bonds [40] Group 10 - Jinkai New Energy plans to distribute a cash dividend of 0.1 yuan per share to shareholders [41] - Tianchen Medical raised the upper limit for share repurchase to 70 yuan per share [42] - Tianmu Lake used 38 million yuan of idle funds to purchase structured deposits [43]

Core Viewpoint - Maiwei Biotech (688062) has received approval from the National Medical Products Administration for the clinical trial of its drug 9MW3811, aimed at treating pathological scars in a Phase II study [1] Company Summary - 9MW3811 is a humanized monoclonal antibody targeting human IL-11, developed independently by Maiwei Biotech [1] - The drug is classified as a Class 1 therapeutic biological product and holds independent intellectual property rights [1]